Revolutionizing Kidney Disease Treatment: Rege Nephro Secures $17M in Series B Funding

Rege Nephro, a pioneering clinical-stage biotech company founded in 2019, has successfully raised $17 million in a recent funding round, marking a significant milestone in its mission to combat chronic kidney disease (CKD) and autosomal dominant polycystic kidney disease (ADPKD). With over 13 million individuals grappling with CKD in Japan alone—340,000 of whom endure the burdensome reality of artificial dialysis—Rege Nephro's innovative approach is both timely and essential. The debilitating healthcare costs associated with dialysis reach a staggering $12 billion, accounting for 4% of Japan's total healthcare expenses, highlighting the critical need for effective and curative treatment options. Unlike existing therapies that merely manage symptoms, Rege Nephro is at the forefront of developing cell therapy utilizing nephron progenitor cells differentiated from induced pluripotent stem (iPS) cells, with the potential to regenerate kidney function. The new funding will be instrumental in advancing their groundbreaking research and clinical trials, aimed at delivering breakthrough therapies that could transform the lives of CKD patients and alleviate the significant healthcare burden resulting from the disease. As the company propels forward, it remains steadfast in its commitment to leading innovation in renal therapies, creating hope for millions affected by kidney diseases and shifting the paradigm towards a future where curative treatments are within reach.